GlassScriptPhysician profile
Debra Barnett
NPI 1609921543
$23,839.42
in general payments reported to CMS, 2019-2025
28 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,372 · 2020: $4,975 · 2021: $1,432 · 2022: $2,605 · 2023: $8,566 · 2024: $1,995 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,681 · Food and Beverage: $5,710 · Education: $63.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,680.95 |
| Food and Beverage | $5,710.44 |
| Education | $63.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $8,271.71 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $3,466.23 | 2019-2025 | Spravato |
| Alkermes, INC. | $2,607.28 | 2019-2024 | Lybalvi, Aristada, Vivitrol |
| Allergan, INC. | $1,410.02 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $1,129.89 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $986.44 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $850.92 | 2021-2025 | Caplyta |
| Abbvie INC. | $784.99 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $720.63 | 2019-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $671.12 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $609.38 | 2019-2025 | Neurostar Tms Therapy System |
| Eisai INC. | $284.47 | 2021 | |
| Indivior INC. | $276.21 | 2022-2025 | Sublocade |
| Avanir Pharmaceuticals, INC. | $252.40 | 2019-2021 | |
| Axsome Therapeutics, INC. | $242.28 | 2024-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $226.86 | 2021-2022 | |
| Lundbeck LLC | $207.88 | 2019-2025 | Rexulti |
| Livanova USA, INC. | $187.59 | 2021 | |
| Corium, LLC | $166.45 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $140.75 | 2019-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $106.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.04 | 2022-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.01 | 2024 | |
| Sage Therapeutics, LLC | $37.26 | 2021-2022 | |
| Braeburn INC. | $28.23 | 2023-2025 | Brixadi |
| Biogen, INC. | $18.88 | 2023 | |
| Sunovion Pharmaceuticals INC. | $18.50 | 2022 | |
| Neos Therapeutics, LP | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.